Q-omics provides the consensus-scored VMA21 profile across patient tissues and cancer cell-line models. VMA21 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, VMA21 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, VMA21 RNA expression shows 20,237 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where VMA21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VMA21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VMA21 survival associations across molecular data types. VMA21 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VMA21 RNA expression–survival associations across cancer types. High VMA21 expression shows unfavorable associations in KIRP, LIHC, COAD, UVM and HNSC, but favorable associations in LUSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for VMA21 RNA expression.
This table summarizes VMA21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for VMA21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VMA21 shows higher tumor expression in HNSC, BLCA, COAD, KIRP, LIHC and KIRC. The HNSC box plot shows higher VMA21 RNA expression in tumor versus normal tissue (log2 FC = +1.477, t-test p < 0.001).
This table shows molecular features associated with VMA21 in patient tissues and cancer cell lines. In patient samples, VMA21 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, VMA21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
